Processa Pharmaceuticals, Inc. Right-of-Use Asset Obtained in Exchange for Finance Lease Liability
Processa Pharmaceuticals, Inc. (PCSA) reported Right-of-Use Asset Obtained in Exchange for Finance Lease Liability of $11.80 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability · last filed 2026-03-18
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for finance lease liability for the quarter ending 2024-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for finance lease liability for the quarter ending 2024-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for finance lease liability for the quarter ending 2024-06-30 was $0.00.
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for finance lease liability for the quarter ending 2024-03-31 was $11.80K.
- Processa Pharmaceuticals, Inc. right-of-use asset obtained in exchange for finance lease liability for fiscal 2024 was $11.80K.
| Period end | Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Finance Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $0.00 derived: sum of 2 quarters · filed 2026-03-18 | $0.00 derived: sum of 3 quarters · filed 2026-03-18 | $11.80K 10-K · filed 2026-03-18 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $11.80K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $11.80K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $11.80K 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |